MCID: PRR002
MIFTS: 51

Pure Red-Cell Aplasia

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Pure Red-Cell Aplasia

MalaCards integrated aliases for Pure Red-Cell Aplasia:

Name: Pure Red-Cell Aplasia 12 15 73
Pure Red Cell Aplasia 12 76 53
Primary Red Cell Aplasia 12
Red-Cell Aplasia, Pure 44
Red-Cell Aplasia Pure 55
Red Cell Hypoplasia 12
Prca 53

Classifications:



External Ids:

Disease Ontology 12 DOID:1340
MeSH 44 D012010
NCIt 50 C34974
UMLS 73 C0034902

Summaries for Pure Red-Cell Aplasia

NIH Rare Diseases : 53 Pure red cell aplasia (PRCA) is a rare condition that affects the bone marrow. Bone marrow contains stem cells which develop into the red blood cells that carry oxygen through the body, the white blood cells that fight infections, and the platelets that help with blood clotting. In people with PRCA, the bone marrow makes a reduced number of red blood cells (called anemia). As a result, affected people may experience fatigue, lethargy, and pale skin. PRCA has many different causes. A rare congenital form of PRCA, called Diamond Blackfan syndrome, is an inherited condition that is also associated with other physical abnormalities. PRCA can also be due to certain medications, infections, pregnancy, renal failure, and conditions such as thymomas, autoimmune disease (such as systemic lupus erythematosus), cancers of the blood, and solid tumors. In many cases, the cause of the condition is unknown (idiopathic). The treatment of PRCA aims to address the underlying cause of the condition and relieve the associated signs and symptoms.

MalaCards based summary : Pure Red-Cell Aplasia, also known as pure red cell aplasia, is related to large granular lymphocyte leukemia and chronic graft versus host disease. An important gene associated with Pure Red-Cell Aplasia is EPO (Erythropoietin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Iron and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Pure red cell aplasia (PRCA) or erythroblastopenia refers to a type of anemia affecting the precursors... more...

Related Diseases for Pure Red-Cell Aplasia

Diseases related to Pure Red-Cell Aplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 238)
# Related Disease Score Top Affiliating Genes
1 large granular lymphocyte leukemia 31.6 IL2RA STAT3
2 chronic graft versus host disease 31.0 ALB IL2RA
3 t-cell large granular lymphocyte leukemia 30.9 IL2 STAT3
4 chronic kidney failure 30.4 ALB EPO TF
5 kwashiorkor 30.4 ALB TF
6 marasmus 30.4 ALB TF
7 celiac disease 1 30.3 ALB HLA-A IL2
8 hepatitis e 30.1 ALB RPS17
9 acute disseminated encephalomyelitis 30.0 HLA-B HLA-DRB1
10 hematopoietic stem cell transplantation 30.0 HLA-A HLA-B IL2
11 hemosiderosis 29.8 EPO TF
12 myeloma, multiple 29.8 ALB EPO IL2 STAT3
13 sclerosing cholangitis 29.6 ALB HLA-B HLA-DRB1
14 cholangitis 29.6 ALB HLA-B HLA-DRB1
15 systemic lupus erythematosus 29.2 ALB HLA-DRB1 IL2 IL2RA
16 graft-versus-host disease 29.1 HLA-A HLA-B HLA-DRB1 IL2
17 rheumatoid arthritis 28.7 HLA-B HLA-DRB1 IL2 IL2RA
18 autoimmune disease 27.9 HLA-B HLA-DRB1 IL2 IL2RA STAT3
19 aplastic anemia 26.5 EPO HLA-A HLA-B HLA-DRB1 IL2 RPS17
20 acquired pure red cell aplasia 12.9
21 transient erythroblastopenia of childhood 12.2
22 diamond-blackfan anemia 11.6
23 thymoma 10.8
24 leukemia 10.7
25 calciphylaxis 10.7 ALB EPO
26 splenic disease 10.7 ALB EPO
27 anteroseptal myocardial infarction 10.7 ALB HLA-DRB1
28 fetal erythroblastosis 10.6 ALB EPO
29 rh isoimmunization 10.6 ALB EPO
30 hemorrhagic fever 10.6 ALB HLA-DRB1
31 hemolytic anemia 10.6
32 rheumatoid factor-negative juvenile idiopathic arthritis 10.6 HLA-DRB1 IL2RA
33 hepatitis 10.6
34 lymphoma 10.6
35 renal hypertension 10.6 ALB EPO
36 lupus erythematosus 10.6
37 anemia, autoimmune hemolytic 10.6
38 secondary hyperparathyroidism of renal origin 10.6 ALB EPO
39 leukemia, chronic lymphocytic 2 10.5
40 leukemia, chronic lymphocytic 10.5
41 leukemia, b-cell, chronic 10.5
42 autoimmune enteropathy 10.5 IL2RA STAT3
43 berylliosis 10.5 HLA-DRB1 IL2
44 recurrent respiratory papillomatosis 10.5 HLA-DRB1 IL2
45 myasthenia gravis 10.5
46 myasthenia gravis congenital 10.5
47 capillary disease 10.5 ALB IL2
48 myelodysplastic syndrome 10.4
49 oligoarticular juvenile idiopathic arthritis 10.4 HLA-DRB1 IL2RA
50 microscopic colitis 10.4 HLA-DRB1 IL2

Graphical network of the top 20 diseases related to Pure Red-Cell Aplasia:



Diseases related to Pure Red-Cell Aplasia

Symptoms & Phenotypes for Pure Red-Cell Aplasia

GenomeRNAi Phenotypes related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.75 HLA-A HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.75 RPS17
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.75 HLA-A HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.75 RPS17
5 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.75 HLA-A HLA-B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.75 HLA-A HLA-B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.75 RPS17
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.75 RPS17
9 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.75 HLA-A HLA-B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.75 HLA-A HLA-B
11 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.75 RPS17
12 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.75 HLA-A HLA-B
13 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.75 RPS17
14 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.75 RPS17
15 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.75 HLA-A HLA-B RPS17
16 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.75 HLA-A HLA-B
17 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.75 RPS17

Drugs & Therapeutics for Pure Red-Cell Aplasia

Drugs for Pure Red-Cell Aplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Deferasirox Approved, Investigational Phase 4,Phase 3,Phase 2 201530-41-8 5493381
4
Darbepoetin alfa Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11096-26-7, 209810-58-2
5
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
6
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
7 Epoetin alfa Phase 4,Phase 3,Phase 2 113427-24-0
8 Hematinics Phase 4,Phase 3,Phase 2,Not Applicable
9 Antibodies Phase 4,Phase 3,Phase 2
10 Immunoglobulins Phase 4,Phase 3,Phase 2
11 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Liver Extracts Phase 4
15 Micronutrients Phase 4,Phase 3
16 Chelating Agents Phase 4,Phase 3,Phase 2
17 Trace Elements Phase 4,Phase 3
18 Iron Chelating Agents Phase 4,Phase 3,Phase 2
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21
Lenograstim Approved, Investigational Phase 2, Phase 3,Not Applicable 135968-09-1
22
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
23
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
24
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
25
Vidarabine Approved, Investigational Phase 2, Phase 3,Phase 3 24356-66-9 32326 21704
26
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1 216503-57-0
27
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
28
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
29
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
30
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
31
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
32 tannic acid Approved, Nutraceutical Phase 3,Phase 2
33 Orange Approved, Nutraceutical Phase 3
34 Prednisolone acetate Phase 3,Phase 2,Not Applicable
35 Alkylating Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
36 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
37 Methylprednisolone acetate Phase 3,Phase 2,Not Applicable
38 Methylprednisolone Hemisuccinate Phase 3,Phase 2,Not Applicable
39 Gastrointestinal Agents Phase 3,Phase 2,Not Applicable
40 Neuroprotective Agents Phase 3,Phase 2,Not Applicable
41 Cyclosporins Phase 3,Phase 2,Phase 1,Not Applicable
42 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
43 Dermatologic Agents Phase 3,Phase 2,Not Applicable
44 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
46 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
47 Prednisolone hemisuccinate Phase 3,Phase 2,Not Applicable
48 Prednisolone phosphate Phase 3,Phase 2,Not Applicable
49 Antiemetics Phase 3,Phase 2,Not Applicable
50 Protective Agents Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4
2 Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v. Completed NCT00632125 Phase 4 HX575 recombinant human erythropoietin alfa
3 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropo Completed NCT00773513 Phase 4 Darbepoetin Alfa;Epoetin Alfa;Epoetin Beta;methoxy polyethylene glycol-epoetin beta
4 Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Completed NCT00673608 Phase 4 deferasirox
5 Tacrolimus Treatment for Refractory PRCA Recruiting NCT03540472 Phase 4 tacrolimus
6 Sirolimus Treatment for Refractory PRCA Recruiting NCT03364764 Phase 4 Sirolimus
7 Efficacy and Safety Study of GerEPO Completed NCT00229099 Phase 3 GerEPO
8 Iron Sucrose in Stage 3/4 Kidney Disease Completed NCT00202345 Phase 3 Iron sucrose
9 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed NCT00235391 Phase 3 Deferasirox
10 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
11 Stem Cell Transplant for Hemoglobinopathy Active, not recruiting NCT00176852 Phase 2, Phase 3 Busulfan, Fludarabine, ATG, TLI;Busulfan, Cyclophosphamide, ATG, GCSF;Campath, Fludarabine, Cyclophosphamide
12 Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy Not yet recruiting NCT03163589 Phase 3 Erythropoietin;normal saline
13 Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment Terminated NCT01288131 Phase 3 Cyclosporine combine with mycophenolate mofetil;Cyclophosphamide + pred
14 A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer Terminated NCT00246597 Phase 3 epoetin alfa
15 Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Terminated NCT00858364 Phase 3 Darbepoetin alfa;Placebo
16 Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease Terminated NCT00436748 Phase 3 Darbepoetin Alfa;Placebo
17 L-leucine in Diamond Blackfan Anemia Patients Unknown status NCT02386267 Phase 2 L-leucine
18 Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Completed NCT00229619 Phase 2 Rituximab
19 Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease Completed NCT00314795 Phase 2 peginesatide
20 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
21 A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Completed NCT01044186 Phase 2 ICL670
22 Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia Completed NCT00011505 Phase 2 G-CSF
23 Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remi Completed NCT00305708 Phase 1, Phase 2 busulfan;fludarabine phosphate
24 Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders Completed NCT00301834 Phase 2 busulfan;cyclosporine;fludarabine phosphate;methotrexate;methylprednisolone
25 Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias Completed NCT00061763 Phase 2 Deferasirox
26 Medical Treatment for Diamond Blackfan Anemia Completed NCT00001749 Phase 2 Antithymocyte globulin;Cyclosporine
27 Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor Recruiting NCT03214354 Phase 2 Alemtuzumab;Sirolimus
28 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure Recruiting NCT02105766 Phase 1, Phase 2 Alemtuzumab;Sirolimus;Cyclophosphamide;Pentostatin;Radiotherapy
29 Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia Recruiting NCT01464164 Phase 1, Phase 2 Sotatercept;Sotatercept with prednisone boost
30 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
31 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Recruiting NCT01174108 Phase 2
32 Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias Recruiting NCT00061568 Phase 2 Alemtuzumab (Campath );Sirolimus (Rapamune )
33 Busulfan, Fludarabine, and Thiotepa Conditioning Regimen for Non Malignant Disease Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
34 Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia Active, not recruiting NCT01362595 Phase 1, Phase 2 leucine
35 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Active, not recruiting NCT00003838 Phase 2
36 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
37 Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies Suspended NCT01419704 Phase 1, Phase 2
38 A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure Terminated NCT00001962 Phase 2 Daclizumab
39 The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias Terminated NCT00472433 Phase 2 Alemtuzumab
40 A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002) Terminated NCT00968617 Phase 2 MK2578;MK2578;MK2578;Comparator: darbepoetin alfa
41 A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12) Terminated NCT00924781 Phase 2 MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline;MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline;MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
42 Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Terminated NCT02512679 Phase 2 Cyclophosphamide Dose Level 1;Cyclophosphamide Dose Level 2;Cyclophosphamide Dose Level 3;Cyclophosphamide Dose Level 4
43 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs Terminated NCT00957931 Phase 2
44 BMT Abatacept for Non-Malignant Diseases Recruiting NCT01917708 Phase 1 Abatacept
45 Human Placental-Derived Stem Cell Transplantation Active, not recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
46 Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia Terminated NCT01034592 Phase 1 Lenalidomide
47 Identifying Characteristics of Bone Marrow Failure Syndromes Unknown status NCT00315419
48 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 Not Applicable anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
49 Multi-Center Study of Iron Overload: Survey Study (MCSIO) Unknown status NCT01913548
50 Multi-Center Study of Iron Overload: Pilot Study Unknown status NCT01114776

Search NIH Clinical Center for Pure Red-Cell Aplasia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: red-cell aplasia, pure

Genetic Tests for Pure Red-Cell Aplasia

Anatomical Context for Pure Red-Cell Aplasia

MalaCards organs/tissues related to Pure Red-Cell Aplasia:

41
Bone, Bone Marrow, Kidney, T Cells, Skin, Liver, B Cells

Publications for Pure Red-Cell Aplasia

Articles related to Pure Red-Cell Aplasia:

(show top 50) (show all 659)
# Title Authors Year
1
Recovery of Pure Red Cell Aplasia Following Hematopoietic Stem Cell Transplantation Associated with IL-6 Elevation Caused by Odontogenic Infection. ( 29877260 )
2018
2
Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation. ( 29079126 )
2018
3
The clinical characteristics and therapy response of patients with acquired pure red cell aplasia. ( 29754581 )
2018
4
Pure red cell aplasia with t-cell large granular lymphocytic leukemia. ( 29921385 )
2018
5
Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia in Thymoma. ( 29713553 )
2018
6
Sirolimus for the treatment of multi-resistant pure red cell aplasia. ( 29741762 )
2018
7
Del(5q) myelodysplastic syndrome combined with pure red cell aplasia. ( 29963514 )
2018
8
Pure red cell aplasia and HIV infection: what to suspect? ( 29680800 )
2018
9
Rational management approach to pure red cell aplasia. ( 29217782 )
2018
10
Identification of mutations in patients with acquired pure red cell aplasia. ( 29767669 )
2018
11
An Unexpected Cause of Acute Enteritis in a Patient with Pure Red Cell Aplasia Parvovirus B19-Associated Acute Enteritis. ( 29610498 )
2018
12
Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center. ( 29589280 )
2018
13
Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. ( 28543448 )
2017
14
Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients. ( 28042550 )
2017
15
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
16
Successful treatment of tacrolimus-related pure red cell aplasia and autoimmune hemolytic anemia with rituximab in a pediatric cardiac transplant patient. ( 28598573 )
2017
17
T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia. ( 29296951 )
2017
18
Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation. ( 28488966 )
2017
19
A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma. ( 28872489 )
2017
20
Use of Nandrolone Decanoate in Treatment of Pure Red Cell Aplasia Secondary to Diclofenac Administration: A Case Report. ( 28750791 )
2017
21
Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature. ( 28924112 )
2017
22
Trend and treatment patterns of aplastic anemia in Korea, pure red cell aplasia and myelodysplastic syndrome in Korea: a nation-wide analysis. ( 28664500 )
2017
23
Cyclosporin A Reversed Chemoresistance of a Patient with Pure Red Cell Aplasia Secondary to Thymoma. ( 28739760 )
2017
24
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib. ( 27756158 )
2017
25
Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2. ( 28230570 )
2017
26
Pure red cell aplasia and myasthenia gravis: a patient having both autoimmune conditions in the absence of thymoma. ( 28893803 )
2017
27
Pure Red Cell Aplasia Due to Parvovirus B19: Erythropoietin-Resistant Anemia in a Pediatric Kidney Recipient. ( 28387173 )
2017
28
Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review. ( 28182355 )
2017
29
Pure Red Cell Aplasia Associated with Good Syndrome. ( 28382272 )
2017
30
Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation. ( 27642338 )
2016
31
Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine. ( 28509169 )
2016
32
Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab. ( 27382560 )
2016
33
TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib. ( 27843612 )
2016
34
Post renal transplant pure red cell aplasia-is tacrolimus a culprit? ( 27478605 )
2016
35
Monoclonal gammopathy-associated pure red cell aplasia. ( 26999424 )
2016
36
Unusual co-occurrence of Evans syndrome and pure red cell aplasia in elderly patient with prostate cancer. ( 27465154 )
2016
37
Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study. ( 26708119 )
2016
38
Pure red cell aplasia caused by parvovirus B19 in a heart transplant recipient. ( 27648265 )
2016
39
Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. ( 26981948 )
2016
40
Pure Red Cell Aplasia Following Interleukin-2 Therapy. ( 27144182 )
2016
41
Holoprosencephaly and Pure Red Cell Aplasia in a Feline Leukaemia Virus-Positive Kitten. ( 26897097 )
2016
42
Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus. ( 27338269 )
2016
43
Coombs-negative Autoimmune Hemolytic Anemia Followed by Anti-erythropoetin Receptor Antibody-associated Pure Red Cell Aplasia: A Case Report and Review of Literature. ( 26935373 )
2016
44
Pure red cell aplasia. ( 27881371 )
2016
45
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. ( 26921820 )
2016
46
Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia. ( 26968551 )
2016
47
Pure red cell aplasia induced by epoetin zeta. ( 27478604 )
2016
48
Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab. ( 27408396 )
2016
49
Invasive Thymoma with Pure Red Cell Aplasia and Amegakaryocytic Thrombocytopenia. ( 28053696 )
2016
50
Dapsone-induced pure red cell aplasia and cholestatic jaundice: A new experience for diagnosis and management. ( 27512715 )
2016

Variations for Pure Red-Cell Aplasia

Expression for Pure Red-Cell Aplasia

Search GEO for disease gene expression data for Pure Red-Cell Aplasia.

Pathways for Pure Red-Cell Aplasia

Pathways related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 HLA-A HLA-B HLA-DRB1 IL2 IL2RA STAT3
2
Show member pathways
12.75 EPO HLA-A HLA-B IL2 IL2RA
3 12.63 EPO IL2 IL2RA STAT3
4
Show member pathways
12.62 HLA-A HLA-B HLA-DRB1 IL2 IL2RA TRB
5
Show member pathways
12.49 HLA-A HLA-B HLA-DRB1 IL2 IL2RA STAT3
6
Show member pathways
12.33 EPO HLA-A HLA-B IL2 IL2RA STAT3
7
Show member pathways
12.23 HLA-DRB1 IL2 IL2RA STAT3
8 12.17 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
9 12.1 HLA-A HLA-B STAT3
10 12.08 HLA-A HLA-B HLA-DRB1 STAT3
11 11.96 HLA-A HLA-B HLA-DRB1
12 11.93 HLA-A HLA-B HLA-DRB1
13
Show member pathways
11.89 IL2 IL2RA STAT3
14
Show member pathways
11.85 IL2 IL2RA STAT3
15 11.81 EPO IL2 IL2RA
16
Show member pathways
11.79 HLA-DRB1 IL2 IL2RA STAT3 TRB
17 11.73 EPO STAT3 TF
18 11.71 EPO HLA-DRB1 IL2RA
19 11.7 EPO IL2 IL2RA STAT3
20
Show member pathways
11.46 HLA-A IL2 IL2RA
21 11.15 IL2 IL2RA
22
Show member pathways
11.15 HLA-A HLA-DRB1 IL2 IL2RA STAT3 TRB
23 11.12 IL2 TRB
24 11.09 HLA-DRB1 IL2 TRB
25
Show member pathways
11.08 IL2RA STAT3
26 11 HLA-A HLA-B
27 10.7 HLA-DRB1 IL2 IL2RA STAT3

GO Terms for Pure Red-Cell Aplasia

Cellular components related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 9.33 HLA-A HLA-B HLA-DRB1
2 MHC class I protein complex GO:0042612 9.26 HLA-A HLA-B
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-A HLA-B HLA-DRB1
4 cell surface GO:0009986 9.1 EPO HLA-A HLA-B HLA-DRB1 IL2RA TF

Biological processes related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.87 ALB EPO IL2 STAT3
2 viral process GO:0016032 9.84 HLA-A HLA-B HLA-DRB1 STAT3
3 immune system process GO:0002376 9.77 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
4 immune response GO:0006955 9.65 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
5 interferon-gamma-mediated signaling pathway GO:0060333 9.63 HLA-A HLA-B HLA-DRB1
6 acute-phase response GO:0006953 9.58 EPO STAT3
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 EPO IL2 STAT3
8 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.56 HLA-A HLA-B
9 positive regulation of T cell differentiation GO:0045582 9.55 IL2 IL2RA
10 regulation of regulatory T cell differentiation GO:0045589 9.52 IL2 IL2RA
11 inflammatory response to antigenic stimulus GO:0002437 9.51 HLA-DRB1 IL2RA
12 interleukin-2-mediated signaling pathway GO:0038110 9.49 IL2 IL2RA
13 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.48 HLA-A HLA-B
14 negative regulation of lymphocyte proliferation GO:0050672 9.43 IL2 IL2RA
15 antigen processing and presentation GO:0019882 9.33 HLA-A HLA-B HLA-DRB1
16 protection from natural killer cell mediated cytotoxicity GO:0042270 9.32 HLA-A HLA-B
17 regulation of T cell homeostatic proliferation GO:0046013 8.96 IL2 IL2RA
18 positive regulation of activated T cell proliferation GO:0042104 8.8 EPO IL2 IL2RA

Molecular functions related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.8 HLA-A HLA-B HLA-DRB1

Sources for Pure Red-Cell Aplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....